Agreement marks a significant step in Arcera’s strategy to strengthen its cardiometabolic franchise and broaden its portfolio of innovative medicines across international markets.
Abu Dhabi, UAE / Hong Kong, China, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Arcera Life Sciences (“Arcera”), an international life sciences company headquartered in Abu Dhabi, UAE, and Innogen Pharmaceuticals (“Innogen”) (HKEX: 2591), a Shanghai-based biopharmaceutical company focused on metabolic diseases, today announced an exclusive licensing and commercialization agreement for Efsubaglutide Alfa, a GLP-1 receptor agonist therapy across key international markets, including the UAE.
The agreement brings together Innogen’s expertise in metabolic diseases with Arcera’s regulatory, market access and commercial capabilities, establishing cardiometabolic disease as a core pillar of Arcera’s portfolio. It also reflects Arcera’s ambition to be a partner of choice for bringing differentiated innovative medicines to patients in international markets.
Under the agreement, Arcera will be responsible for regulatory activities, market access and commercialization of the therapy across agreed territories spanning selected countries in Africa, Eastern Europe, Latin America and the Middle East. Innogen will receive an upfront payment and will be eligible for milestone payments and tiered royalties on net sales of the product in the licensed territories.

Cardiometabolic diseases, including obesity and type 2 diabetes, represent a substantial and growing healthcare burden globally. According to the International Diabetes Federation, 589 million adults worldwide are living with diabetes, a number projected to reach 853 million by 2050. This partnership between Arcera and Innogen is a step toward wider access to advanced metabolic therapies.
GLP-1 receptor agonists are a class of therapy used in the management of type 2 diabetes and, increasingly, obesity. In 2025, the World Health Organization added GLP-1 therapies to its Model List of Essential Medicines and issued a global guideline on their use in treating obesity, a condition affecting more than one billion people worldwide. For Arcera, the agreement strengthens its presence in this therapy area and creates a platform for further growth in cardiometabolic medicine across its international markets.
Efsubaglutide Alfa is a fusion protein comprising a human GLP-1 analogue and an IgG Fc fragment, with a half-life of up to 280 hours across different studies. Clinical studies showed HbA1c reductions of approximately 2.2 percentage points at Week 24. Clinical studies in Chinese adults with overweight or obesity showed that 18 weeks of treatment achieved average weight reductions of 10.6% with once-weekly (QW) dosing and 9.7% with once-every-two-weeks (Q2W) dosing.
The study also observed improvements in body-composition. The muscle-to-fat ratio increased by up to 45.3% from baseline with QW dosing, with weight loss driven predominantly by a reduction in fat mass, indicating fat reduction with relative preservation of muscle. Liver fat content was reduced by up to 51.8% with QW dosing. The incidence of gastrointestinal adverse events was low relative to other GLP-1 receptor agonists (based on cross-trial comparisons), no participants discontinued treatment due to adverse events during an 18-week treatment period, and the treatment was well tolerated. Innogen has also completed a Phase II clinical trial in adults with overweight or obesity in Australia, evaluating the efficacy and safety of once-monthly (Q4W) dosing. The study generated further clinical evidence to support the product’s future global registration and commercialization.
Isabel Afonso, Chief Executive Officer of Arcera Life Sciences, said: “Cardiometabolic diseases remain among the most pressing healthcare challenges in the markets we serve. Our agreement with Innogen accelerates the bridge we are building between China and our international markets to bring innovative medicines to more patients and strengthen our cardiometabolic portfolio. By combining our partners’ scientific capabilities with Arcera’s regulatory expertise, market access and overall commercial reach, we aim to turn innovation into meaningful impact for people living with chronic disease.”
Dr. Qinghua Wang, Founder, Chairman and Chief Executive Officer of Innogen Pharmaceuticals, said: “We are delighted to establish this collaboration with Arcera, which represents an important step in Innogen’s international expansion. We believe that combining world-class science with entrepreneurial innovation is key to improving patient care. Innogen’s mission is to provide best-in-class and first-in-class therapies for people living with diabetes, obesity and other metabolic diseases worldwide. Our collaboration with Arcera is an important step toward this vision. By combining Innogen’s scientific innovation with Arcera’s strengths in international regulatory affairs and commercialization, we aim to broaden access to differentiated therapies and ultimately improve the quality of life of patients around the world.”
The transaction is subject to the customary regulatory and operational requirements applicable in the relevant territories. Commercialization will begin following receipt of the required local regulatory approvals.
END
About Arcera Life Sciences
Arcera Life Sciences is an international life sciences company headquartered in Abu Dhabi, United Arab Emirates. Arcera brings innovative and proven medicines to patients in over 100 countries worldwide, with operations spanning Africa, Eurasia, Latin America, and the Middle East. Arcera commercializes medicines and healthcare products across multiple therapeutic areas, supported by manufacturing and packaging capabilities in eight countries. To expand access to innovative therapies, Arcera partners with leading pharmaceutical and biotech companies, ensuring supply resilience and quality standards. Its portfolio comprises over 2,000 product presentations marketed under 300+ brands in more than 60 direct markets. To learn more about Arcera, visit www.arceralifesciences.com.
About Innogen Pharmaceuticals
Founded in 2014, Innogen Pharmaceuticals (HKEX: 2591) is a biopharmaceutical company focused on the research, development and industrialization of innovative medicines for metabolic diseases. The Company has a wholly self-developed pipeline covering indications including type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, metabolic dysfunction-associated steatohepatitis (MASH) and Alzheimer’s disease (AD), supported by global intellectual property rights and a global patent portfolio. Its core product, Efsubaglutide Alfa, is a next-generation, human-derived, ultra-long-acting GLP-1 receptor agonist developed in-house. It has been approved for the treatment of T2D in mainland China and Macao, China, and has been included in China’s National Reimbursement Drug List (2025 Version). Development of the product received support under China’s 13th Five-Year Plan Major New Drug Innovation program. It has also received the First Prize of the Science and Technology Award of the Chinese Pharmaceutical Association and the First Prize of the Science and Technology Award of the Shanghai Pharmaceutical Association. Innogen has entered the stage of global development and regulatory registration, and its manufacturing facilities have obtained PIC/S GMP certification. The Company is committed to providing better treatment options for patients worldwide. For more information, please visit www.innogenpharm.com.
Attachments
-
DXC 携手 Cisco,通过 DXC OASIS 将 AI 驱动的网络洞察转化为实际行动* DXC 将 Cisco 的 AI 网络智能能力与 DXC OASIS 相结合,通过企业级编排与人工监督,加快事件处置。 * 双方合作将首先聚焦 Cisco Meraki 环境下的办公场所 Wi-Fi2026-11-19
-
Cognizant® Patient Hub Operations 正式推出:AI 赋能的患者治疗支持解决方案,旨在缩短从处方开具到接受治疗的时间Cognizant Patient Hub Operations 基于 NVIDIA 加速计算构建,旨在减少行政流程造成的治疗延误,让患者支持项目能够服务更多患者,而文书工作量无需随之等比例增加。2026-11-19
-
欧莱雅中国获颁全球外资研发中心证书 彰显“全球芯、中国心、未来兴”研发理念上海2026年11月19日 美通社 -- 第四十三批跨国公司地区总部和研发中心颁证仪式昨日举行,欧莱雅中国获颁全球外资研发中心证书。此前,欧莱雅旗下专注于体外重建人体皮2026-11-19
-
华纳音乐集团首席执行官 Robert Kyncl 将在 CES 2027 上探讨音乐的未来作为首位发表 CES 官方主题演讲的音乐公司掌门人,Kyncl 将前瞻音乐创作与互动的全新阶段 弗吉尼亚州阿灵顿2026年11月19日 美通社 -- 美国消费技术协会(CTA)® 《ht2026-11-19
-
品牌一致性背后的运营挑战,Monotype(蒙纳字库)最新研究带来哪些发现?Monotype 研究显示,62% 的受访者将字体缺失或不匹配列为工作流中的三大痛点之一,这凸显了维系品牌一致性所面临的运营难题。 马萨诸塞州沃本2026年11月19日 美通社2026-11-19
-
AMD股价暴跌17%创近9年之最,苏姿丰紧急回应:AI增速远超想象
-
锚定健康中国新征程!第一届医药信息传播论坛将于广州启幕
-
Ledger 中国销售渠道说明:广州馨潇贸易有限公司官方直营渠道公示
-
江苏省脑机接口产业联盟在宁成立,麦澜德分享前沿成果
-
艾芬达入选国家知识产权强国建设示范创建对象:二十载长期主义,兑现每一份用户价值
-
Esentia宣布成功完成2033年到期的6.125%优先票据和2038年到期的6.500%优先票据的定价
-
中荷人寿北京分公司成功举办中荷创享家品牌发布暨协同发展启航仪式
-
华为系具身智能公司具脑磐石完成新一轮融资:对标JEPA,押注类脑智能的认知世界模型
-
北京暑假补习班有哪些?家长首推一对一权威机构金博升学
-
上海高新技术企业代理机构深度访谈与推荐

